Pharmaceuticals announced that a new patent has been granted by the Indian Patent Office in March 2025. This patent relates to DNA ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

Pivot to U.S.-based Supply Chain for Critical Input Materials Completed - STONY BROOK, NY / ACCESS Newswire / April 21, 2025 ...

DNA detection at baseline was associated with worse recurrence-free, overall survival in BRAFV600-mutant stage III melanoma.

PCR genetic analysis has been in the spotlight since COVID-19, but light is now further facilitating PCR-free methods. Osaka ...

This patent relates to DNA Polymerase IIIC Inhibitors, including compositions-of-matter. This is the latest in the series of granted patents and pending patent applications that Acurx has file ...

A new study from Weill Cornell Medicine provides insights into how cells maintain the tiny end caps of chromosomes as they ...

The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA ...

A medical breakthrough could result in the first treatment for rare but serious diseases in which genetic defects disrupt ...